The 9/11 terror attacks: Emotional consequences persist for children

Article

The continuing psychological effects of the terrorist attacks of 9/11/01 are felt nationwide. Pediatricians can be an important source of credible, clear information and advice for parents, and can help distinguish typical reactions from those that may require further assessment.

Recent Videos
Russell Libby, MD, FAAP
Greg Forlenza, MD
Lawrence Eichenfield, MD
Nathan Kuppermann, MD, MPH
COVID-19 Roundtable: Considering off label therapies
Greg Forlenza, MD
Greg Forlenza, MD
COVID-19 Therapy Roundtable: Focusing on Inpatient Care | Image credit: Production Perig
Image credit: Production Perig
Related Content
The REACH Institute

The Reach Institute addresses rising cases of youth depression with new program for primary care providers

The REACH Institute
January 13th 2025
Article

Course grounded in behavior change science combines hands-on CBT techniques with sustained support to enhance pediatric mental health care.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
Weekly review: New peanut patch data, norovirus outbreaks, and more

Weekly review: New peanut patch data, norovirus outbreaks, and more

Joshua Fitch, Senior Editor
January 13th 2025
Article

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
Data: 80% of INZ-701-treated infants with ENPP1 Deficiency survived past first year | Image Credit: © Bostan Natalia - © Bostan Natalia - stock.adobe.com.

Data: 80% of INZ-701-treated infants with ENPP1 Deficiency survived past first year

Joshua Fitch, Senior Editor
January 10th 2025
Article

Positive interim data was reported from the ENERGY 1 trial and Expanded Access Program that featured a total of 5 infants and 1 child.

New data: Viaskin Peanut patch improves treatment benefit through 36 months | Image Credit: © andersphoto - © andersphoto - stock.adobe.com.

New data: Viaskin Peanut patch improves treatment benefit through 36 months

Joshua Fitch, Senior Editor
January 9th 2025
Article

In an open-label extension of the EPITOPE phase 3 trial, the Viaskin Peanut patch had continued improvement in toddlers aged 1-3 years through 36 months.

© 2025 MJH Life Sciences

All rights reserved.